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Abstract
Background: The valsalva manoeuvre is an internationally recommended initial treatment for supraventricular
tachycardia (SVT). The pre-hospital use of a valsalva assist device, to help deliver this manoeuvre, could improve
cardioversion rates and reduce the need for patients to attend hospital.
Methods: We conducted a randomised controlled feasibility trial comparing ambulance clinician use of a valsalva
assist device versus standard care to treat adult patients presenting to an ambulance service in the south west of
England. Eligible consenting participants were randomised 1:1 to device or standard care with trial procedures
mirroring a proposed definitive trial.
Feasibility was assessed upon ambulance clinician and participant recruitment rates and feedback, data
completeness and potential future primary outcome rates.
Results: Over a 6 months period (1 July to 31 December 2018), 276 (23%) of 1183 eligible ambulance clinicians
were trained and they recruited 34 participants; approximately 10% of patients presenting with suspected SVT
during that time. Seventeen participants were randomised to each arm and all underwent their allocated valsalva
strain method. All trial data and 63/68 (93%) of pre and post-valsalva ECGs were available. Seven (21%) participants
had ineligible initial rhythms on retrospective expert ECG review. Valsalva assist device use was associated with
cardioversion and non-conveyance in 4 (24%) and 2 (12%) participants respectively. No participants assigned to
standard care were cardioverted and all were conveyed. Participant feedback highlighted the challenges of
retaining trial information during an SVT attack.
Conclusions: The trial achieved efficient clinician training, randomisation and data collection, and there was an
encouraging effect signal associated with device use. However, trial design changes should be considered to
address the relatively small proportion of eligible patients recruited and challenges identified with consent and
confirmation of cardioversion as a primary outcome.
Trial registration: The trial was registered with ClinicalTrials.gov (NCT03514628) on 2 May 2018.
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Background
Supraventricular tachycardia (SVT) is a heart rhythm
disorder with an estimated incidence of 35 episodes per
100,000 persons per year [1]. Episodes of this tachyar-
rhythmia frequently affect otherwise healthy individuals,
are unpleasant and disruptive to patients’ lives [2]. Pa-
tients frequently seek medical help during attacks of
SVT with many being attended by ambulance services
and subsequently conveyed to an emergency department
(ED) [3] An Australian regional ambulance service saw
over 800 episodes a year [4], and an (unpublished) ser-
vice evaluation by the UK’s South Western Ambulance
Service NHS Foundation Trust (SWASFT), suggests a
similar number are seen by this service.
The valsalva manoeuvre (VM) is a safe, internationally
recommended, first line physical treatment for SVT [5,
6]. It causes slowing of the heart mediated by the vagus
nerve which can terminate attacks (cardioversion) [7]. If
this can be achieved by patients themselves or by pre-
hospital emergency clinicians, conveyance to hospital
and unpleasant second line intravenous treatments (such
as adenosine) might be avoided [4, 8, 9].
Although the VM has historically had a relatively low
(5–27%) rate of cardioversion in clinical practice [10],
recent studies have shown that higher cardioversion
rates approaching 50% can be achieved using a postural
modification (the modified VM) and a 40-mmHg, 15-s
strain delivered with a modified sphygmomanometer
[11, 12]. Such manometers are not routinely carried by
ambulance services and they also could not realistically
be given to patients for use out of hospital (attacks can
recur and patients can perform their own VM).
Blowing into an empty syringe has been used as an al-
ternative [13], but these are unreliable in providing cor-
rect and consistent pressures [14–16]. A valsalva assist
device (VAD) [Meditech Systems Ltd] has recently been
developed. It has been designed to provide the recom-
mended resistance to exhalation at a pressure of 40
mmHg, is small and portable and can be conveniently
packaged with clear instructions on how to correctly
perform the modified VM [17]. If successful, this single
patient use device could then be left with the patient,
should an attack recur.
An evaluation of this device’s effect on cardioversion
and conveyance rates and cost effectiveness in the pre-
hospital setting compared to current techniques would
require a large definitive trial [18]. To determine
whether such a trial is feasible, we designed and con-
ducted a randomised controlled feasibility study in a sin-
gle UK ambulance trust. The specific objectives of the
study were to assess the pre-hospital clinician training
and enrolment rates, the randomisation and consent
processes, participant recruitment rates, data collection,
and the acceptability of device use by pre-hospital
clinicians. The study was designed to mirror a definitive
study and to capture key feasibility data.
Methods
Trial design
We conducted a pragmatic, randomised controlled feasi-
bility trial, with an evaluation of trial processes, comparing
VAD versus standard practice delivered VMs in patients
with SVT presenting to an ambulance service in the south
west of England (SWASFT). Recruitment of participants
and trial interventions were carried out by trial-trained
pre-hospital clinicians of participating ambulance stations.
The trial was registered (NCT03514628), supported
through NIHR research capability funding and sponsored
by SWASFT. Ethical approval for the study was received
from Oxford C REC (18/SC/0111)
Selection of sites and clinician training
Expressions of interest were invited from the larger ambu-
lance stations in the SWASFT region. Twenty-seven sta-
tions volunteered and were selected on the basis of their
interest, size and/or proximity to a larger ‘hub’ station in
case of vehicle redistribution between neighbouring sta-
tions. Station champions were selected to support training
uptake and trial publicity. All eligible ‘lead’ ambulance cli-
nicians (paramedics and ambulance technicians/equiva-
lent) in participating stations were sent invitations to take
part, together with an e-training package which included
an overview of SVT management and the modified VM,
the use of the VAD, proportionate Good Clinical Practice
training and a summary video of trial procedures.
Previous paramedic studies in this region suggested
approximately 8 clinicians per week might be recruited.
A 10-week recruitment period would therefore enable
an estimated 80 study-clinicians to be enrolled.
Participant recruitment
Patients with suspected SVT presenting to trial-trained
SWASFT clinicians were screened according to the fol-
lowing eligibility criteria over a 6-month period:
Inclusion criteria
 Age 18 years and over
 Patient identified by the ambulance clinician as
having SVT* eligible for treatment with the valsalva
manoeuvre
* Regular, narrow complex tachyarrythmia with a QRS
duration < 0.12 ms on ECG
Exclusion criteria
 Unable or unwilling to give informed verbal consent
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 Unstable condition (systolic blood pressure (BP) <
90 mmHg)
 Atrial fibrillation (AF) or atrial flutter on ECG
 Severe hypertension (systolic BP > 220 mmHg or
diastolic BP > 120 mmHg)
 Contraindication or inability to perform a modified
valsalva manoeuvre (any clinical reason in why
patients could not perform a valsalva strain and or
be laid flat and have legs lifted to 45°. For example,
hypotension, haemodynamic instability, recent eye
surgery, or hip problems preventing hip flexion).
 Third trimester pregnancy
 Prisoners
 Previous inclusion in the study
Eligible participants were given an initial verbal ex-
planation of the study using a standard script as a guide
and asked for their verbal consent to take part. Given
the nature of the condition, the challenging setting for
the research and the fact that the proposed intervention
differed from standard practice only in the method used
to generate the valsalva strain, we proposed that wit-
nessed verbal consent was appropriate and proportionate
[19]. The consent process used was carefully discussed
with patient advocates and approved by an ethics com-
mittee experienced in emergency research. However,
feedback on the feasibility and appropriateness of the
consent process used was also an important aspect of
this study.
Randomisation and masking
Participants were randomised 1:1, with variable-sized
blocks, to receive a standard care VM, as determined by
SWASFT guidelines and at the treating clinician’s dis-
cretion (control) or VAD delivered VM (intervention) as
their first treatment. The randomization schedule was
prepared in advance by a statistician. Boxes, containing a
VAD or ‘standard care’ notice, were prepared according
to this schedule by independent volunteers.
Boxes were identical, opaque, masked with internal
packaging to ensure they had the same weight and feel
and closed with a tamper-evident seal. They were pack-
aged with a screening aid memoir and a simple recruit-
ment checklist/data collection form. Boxes were placed
in all ambulance vehicles of participating stations, with
the ECG leads carried on vehicles, for ease of access and
only opened by a participating trial-trained clinician
after an eligible participant had given their consent.
Ambulance stations were given a sufficient stock of se-
quentially numbered boxes to supply all front-line vehi-
cles, with spares to support recruitment. Once a pack
was used, ambulance staff would restock the vehicle on
return to station with the lowest numbered box accord-
ing to a strict log. Use of boxes was followed and audited
by station leads and the research team. This process en-
abled effective randomisation and immediate availability
of trial paperwork, without the need for telephone or
computer use, and was specifically chosen to aid suc-
cessful consecutive recruitment of this patient group in
the pre-hospital setting.
Participants underwent a maximum of three valsalva
manoeuvres at the discretion and direction of the treat-
ing crews according to trial training and SWASFT
guidelines, using the VAD or usual strain method, e.g.
10 ml syringe according to trial allocation. Continuous
ECG monitoring and recording of 12 lead ‘snapshot’
ECGs was available through standard SWASFT monitor-
ing equipment (Ortivus/Physio Control). All other treat-
ment and subsequent management was conducted at the
discretion of the pre-hospital clinicians and according to
national and local guidelines. Of note, SWASFT has a
locally approved protocol for use of the modified val-
salva and non-conveyance of well patients, if their SVT
has cardioverted back to normal sinus rhythm.
After completion of paramedic treatment, participants
were given further written information about the trial
(including advice on what to do should their arrhythmia
re-occur) and asked for confirmation that they were still
willing to be included in the study. They were also of-
fered the device used for their VM (e.g. syringe or VAD)
to take away and asked if they would be willing to take
part in a follow up phone call to seek their opinions
about the research over the next 2 weeks. For consenting
participants, a structured follow up call was conducted
by a member of the research team.
Sample size
A formal sample size calculation was not undertaken for
this feasibility study in which recruitment rate was a pri-
mary outcome. However, based upon the projected para-
medic training rate and SWASFT observational SVT
incidence data, we estimated that we might expect to re-
cruit and randomise approximately 20 patients with SVT
to the study over a 6-month recruitment period. Both
participant and paramedic recruitment were closely
followed during the study to ensure recruitment and
training strategies were effective.
Screening and notification of recruitment was taken
from the pre-hospital clinician electronic patient care
record (ePCR) which has a field to indicate involvement
in a research program. Data collection, as far as possible,
was designed to mirror normal procedures. Key source
data were recorded on the randomisation box cover and
its image captured in the ePCR (which has a camera fa-
cility) before being returned to the researchers in the in-
ternal SWASFT post.
Other source and outcome data were taken from the
ePCR. Clinicians were asked to document return to
Appelboam et al. Pilot and Feasibility Studies            (2020) 6:74 Page 3 of 9
sinus rhythm if noted on continuous ECG monitoring
and to record pre- and post-VM ‘snapshot’ 12-lead
ECGs on the ePCR. These were subsequently checked
by an independent consultant emergency physician,
blind to the crew’s trial allocation. All reported adverse
events were followed up according to good clinical prac-
tice (GCP) principles [20].
Statistical analysis
Analysis of results was conducted according to guide-
lines for feasibility studies, and the ConSORT framework
extension for pilot and feasibility trials was used to re-
port results [21]. The number of participating pre-
hospital clinicians was reported as a number and per-
centage of those approached. Baseline data (e.g. demo-
graphics) were reported descriptively by group and
outcome data as point estimates using suitable measures
(e.g. number and %) in each group, with 95% confidence
intervals. No formal comparison between groups was
undertaken.
Outcome measures
The primary outcome measure for this feasibility study
was the rate of pre-hospital clinician training and par-
ticipant recruitment. Other outcome measures included
the views of participants about the consent process and
other research procedures and the completeness of data.
Potential primary outcomes in a definitive study would
be return to sinus rhythm as determined by the ambu-
lance post-VM 12 lead ECG or the rate of non-
conveyance to hospital. The feasibility of collecting
ECGs and data regarding conveyance and other emer-
gency pre-hospital treatments was also assessed.
Patient and public involvement
Patient and public testimonies about emergency treat-
ment for SVT [22] have driven trials looking for better
non-drug treatment of SVT. Patient involvement with
our previous research and clinical experience has dem-
onstrated that an effective valsalva manoeuvre, with
avoidance of drugs such as adenosine, is associated with
high patient satisfaction and convenience [10].
A local patient and public group (Exeter 10,000) have
previously given an opinion on the concept and rational
for the VAD and were supportive of future trials into its
use [17]. Patients and patient advocates were further in-
volved in the design and conduct of this project, particu-
larly in respect of the consent process and in the trial
management group.
Feedback from participants on their experience of the
research elements in this pilot was also sought through
an invitation to participate in a phone call follow-up
(maximum of 3 attempts to contact). Participants con-
senting to this follow-up underwent a short series of
structured questions about their experience, with further
comments invited and an opportunity to attend a face-
to-face focus group with researchers. Participant views
are vital as to the acceptability of any proposed future
definitive trial design.
Results
Pre-hospital clinician training and recruitment rates
The study was conducted between 1 July and 31 Decem-
ber 2018. Training was offered to 1183 eligible ambu-
lance clinicians in the 27 participating stations. At this
time, SWASFT employed around 2290 ‘lead’ ambulance
clinicians based at 95 stations. As larger stations were
chosen in preference, training was therefore offered to
approximately 52% of all eligible SWASFT clinicians in
this feasibility trial. A total of 276 ambulance clinicians
took up training and were enrolled to recruit patients
presenting with SVT to the trial. This represented ap-
proximately 23% of the eligible clinicians at the partici-
pating stations and 12% of all SWASFT ‘lead’ clinicians.
Almost all of the enrolled clinicians were trained within
the first 3 months of the trial.
Participant recruitment and baseline characteristic
Over the 6 months duration of the study, 468211 inci-
dent calls were received by SWASFT. Of these, 1432
cases had ‘SVT’ or ‘supraventricular tachycardia’ men-
tioned in the electronic patient record (ePCR) and on re-
view, suspected SVT was felt to be associated with the
presenting complaint in approximately 330 of these
cases. From these cases, 34 (10%) participants were
attended and recruited by trial-trained ambulance clini-
cians. See Fig. 1.
Steady state recruitment, after the majority of staff
were trained was approximately 10 participants recruited
per month. Thirty clinicians recruited at least 1 partici-
pant, with two clinicians recruiting 2 participants and
one recruiting three participants. Fourteen of the 27 sta-
tions recruited at least 1 participant (range 1–6). Given
the small numbers involved, the groups were reasonably
matched at baseline for age, sex and past history. See
Table 1.
Randomisation and interventions
All 34 participants gave verbal consent and were rando-
mised. Seventeen participants were randomised to inter-
vention (VAD) and 17 to control. All participants
underwent at least one VM attempt (range 1–3). Of the
participants randomised to VAD, all received a VAD de-
livered VM. For the 17 participants randomised to con-
trol, a strain device in the form of a syringe was used for
all VMs (5 ml size syringe for one participant; 10 ml for
seven participants; 20 ml for eight participants; and
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50ml for one participant). See Table 2 for details of in-
terventions delivered.
Cardioversion and non-conveyance rates
Of the 34 participants, all 17 control participants
remained in SVT with a cardioversion rate of 0% (95%
CI 0–18%). Use of the VAD in the 17 intervention group
participants was associated with cardioversion in 4 par-
ticipants, 24% (95% CI 10% to 47%). The use of a modi-
fied VM (mVM) was similar between the groups with 27
participants (14 intervention, 13 control) undergoing the
mVM as part of their treatment.
Fifteen of the 17 intervention participants and all of
the 17 control participants were conveyed to hospital.
This represents a non-conveyance rate (95% CI) in inter-
vention and control participants of 12% (3% to 34%) and
0% (0% to 18%) respectively.
Data completeness
The method of return of data collection forms was by
post only for five participants, by ePCR photo only for
two participants and by both methods for 27 partici-
pants. Between the two methods of data collection, all
data collection forms from the randomisation boxes
were available for analysis. 63/68 (93%) of trial ECGs (31
pre-VM and 32 post-VM) were available and sufficiently
legible (3 pre-VM and 1 post-VM ECGs had severe
Fig. 1 Consort diagram. SWASFT South Western Ambulance Service NHS Foundation Trust, ePCR Electronic patient record, SVT supraventricular
tachycardia, VM valsalva manoeuvre, VAD valsalva assist device. *Proportion of reasons extrapolated from a detailed review of one
month’s attendances
Appelboam et al. Pilot and Feasibility Studies            (2020) 6:74 Page 5 of 9
electrical interference and 1 post-VM ECG was not re-
corded) to allow independent analysis.
Independent ECG review
On retrospective independent review of ECGs, 7 (21%)
participants (4 control group, 3 intervention group) were
judged to have an ineligible initial rhythm on the pre-
VM ECG (2 AF, 1 broad complex tachycardia and 4
sinus tachycardia) and should have been excluded based
upon the trial eligibility criteria. None of these partici-
pants achieved cardioversion and all were conveyed to
hospital. Post-VM ECG evidence of cardioversion was
independently confirmed in 3 of the 4 participants that
were recorded by the ambulance clinician as having
achieved VM-induced cardioversion (one participant’s
SVT had recurred prior to the ECG). An additional 6
cases were judged to have sinus rhythm shown on the
post-VM ECG after the ambulance clinician had re-
corded that SVT had continued after the VM (3 in each
group). These cases are likely to represent later spontan-
eous cardioversion. Overall, the presence of sinus
rhythm on a post-VM ECG in those judged to have had
an eligible initial ECG rhythm on independent review
was therefore 6/14 (43%) and 3/13 (23%) in intervention
and control groups respectively.
Adverse events
There were no serious adverse events reported. Diz-
ziness was recorded in one intervention participant
and a non-epileptic seizure occurred in one control
participant (who had a known history of frequent
non-epileptic seizures). Both fully resolved without
sequelae.
Table 2 Trial Procedures and outcomes
Intervention (n = 17) Control (n = 17)
VAD delivered VM, n 17 0
Control delivered VM, n 0 17
Mean number of VM attempts, n (range) 2.3 (1–3) 2.7 (1–3)
Modified VM used, n 14 13
Legible pre-VM ECG available, n (%) 16 (94) 15 (88)
Legible post-VM ECG available, n (%) 16 (94) 16 (94)
Cardioversion, n (%, 95%CI)* 4 (24, 10 to 47) 0 (0, 0 to 18)
Not conveyed to hospital, n (%, 95%CI) 2 (12, 3 to 34) 0 (0, 0 to 18)
Total mean (median, range) ambulance episode duration (min) 62 (54, 27 to 117) 58 (61, 29 to 102)
Consent for phone follow-up, n 16 13
Phone follow up completed, n 12 9
Eligible presenting rhythm+, n 14 13
ECG Evidence of cardioversion on post-VM ECG in eligible participants+, n (%) 6 (43%) 3 (23%)
VAD valsalva assist device, VM valsalva manoeuvre, ECG electrocardiograph, CI confidence interval
*As recoded by the recruiting ambulance clinician
+As determined by independent retrospective review of ECGs by the emergency department consultant
Table 1 Participant baseline characteristics
Intervention Control
Age (mean; median; range) 63; 68; 19–84 62; 62; 20–91
Sex (M:F) 10:7 7:10
Evidence concurrent illness 3 8
Previous symptoms of SVT but not documented or diagnosed 4 1
Previous documented SVT 6 5
Previous ablation therapy 1 0
Ischaemic heart disease 5 3
Diabetes 0 2
Hypertension 4 5
Valvular heart disease 0 1
SVT supraventricular tachycardia
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Participant and clinician feedback
Twenty-nine of the 34 participants consented to the
follow-up telephone call and 21 (62%) participants (12
interventions, 9 controls) were contactable. The re-
sponses are summarised in Table 3. In the structured
questions, participants felt that they had been given a
clear verbal explanation for the trial, that they had an
opportunity to ask questions and that they were gener-
ally satisfied with the consent process. Most participants
reported being able to take in the trial information and
that it was easy to decide to take part. However, fewer
participants reported reading or recalling the take home
information, and in the informal comments, over half
those followed up, reported limited recall or ability to
take in information at the time of their presentation.
This finding was supported in the subsequent face-to-
face focus group where participants highlighted the chal-
lenges around the transfer and retention of information
during this acute illness. Despite this, all attendees felt
that it had been appropriate to have been asked to take
part and were pleased that they had had the opportunity
to be involved in this research.
Thirty-seven (13%) clinicians involved in the study
responded to an online survey sent to all those who had
undertaken trial training. Most of this group felt the
consent process used was appropriate or highly appro-
priate, that training was sufficient and all but one clin-
ician (who was indifferent), were highly supportive of a
definitive trial. Data collection and ECG capture were
felt to be manageable in the context of recruiting to the
trial during the routine care of their patients.
Discussion
We have conducted a feasibility trial to assess clinician en-
rolment and participant recruitment rates to a study de-
signed to determine the effects of a device on ambulance
cardioversion and conveyance rates in patients with SVT.
Overall clinician and participant recruitment numbers
exceeded our estimates which were based upon previous
ambulance study training rates. Training and study pro-
cedures were designed to be straight forward. These
were covered in an on-line training package and pro-
moted by local ambulance station champions. We
believe this contributed to the high uptake of clinician
enrolment with nearly a quarter of eligible station clini-
cians taking part. For comparison, this is a similar clin-
ician recruitment rate to that achieved during the
AIRWAYS-2 pre-hospital trial, for which SWASFT was
a trial site, but which required face-to-face training and
took more than four times longer to achieve [23].
The rate of patient recruitment however was approxi-
mately 0.12 participants per trained clinician which was
less than our original projections. If training of all eli-
gible staff was replicated in the other stations across the
SWASFT area with the same clinician and participant
recruitment rate, we might expect approximately 126 pa-
tients to be recruited to a definitive trial, of the same de-
sign, per year. (0.12 × (0.23 × 2288) × 2). Using a ‘steady
state’ recruitment rate of 10 participants per month seen
in the last 2 months of the study across all stations gives
an estimate of 220 participants. However, both estimates
are considerably lower than our screening data and a
previous SWASFT activity analysis suggested (approxi-
mately 600 patients a year presenting to ambulance cli-
nicians with SVT). The lower rate of recruitment might
be due to the perceived or actual barriers of recruiting
to a randomised controlled trial in this setting or the
availability of trial-trained clinicians.
Either way, it is likely that to achieve the level of re-
cruitment required for a definitive randomised con-
trolled trial of a similar design, the study would need to
be conducted in a number of large ambulance trusts. Al-
ternatively, a trial embedded into routine care, such as a
step-wedge design [24], might be able to recruit at a rate
nearer the numbers seen in previous service evaluation.
This would also reduce the potential for clinician and
station participation biases, inherent in this feasibility
study design. For practical resource reasons, generally
larger and geographically clustered stations were chosen
to participate in this study. Although these stations had
similar conveyance rates to non-participating stations
and used the same trust clinical guidelines, stratified
random selection of stations would be recommended in
a definitive trial.
The rates of cardioversion and their associated confi-
dence intervals observed in our study population were
Table 3 Participant feedback phone follow-up
Intervention Control Total
Trial verbal information was clear (agree/neither/disagree) 11/1/0 8/1/0 19/2/0
Opportunity to ask questions (agree/neither/disagree) 10/2/0 9/0/0 19/2/0
Consent process (satisfied/neither/dissatisfied) 11/1/0 9/0/0 20/1/0
Able to take in trial information (agree/neither/disagree) 9/2/1 8/1/0 17/3/1
Able to understand home information (agree/neither/disagree) 6/6/0 0/8/1 6/14/1
Deciding to take part
(Easy/neither/difficult)
11/1/0 9/0/0 20/1/0
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consistent with those reported in pre-hospital practice
which vary widely (4.4% to 57.1%) as most studies are
small [10, 25]. Although the trial was not designed to de-
tect a difference in outcomes between the groups, there
was a signal to suggest a higher rate of cardioversion
and non-conveyance in the participants assigned to
VAD delivered VMs. The rate of modified VM was simi-
lar between the groups; however, we did not collect de-
tails of exactly how the modification was carried out.
One of the benefits of a bespoke device is the accom-
panying instructions to support delivery of an evidence
based modification and it is possible that more clinicians
using the VAD delivered the correct sequence of pos-
tural modifications.
Despite the relatively small number of participants re-
cruited in this feasibility trial, the trial allocation process
was efficient with equal numbers assigned to interven-
tion and control and, despite the challenges associated
with conducting a pre-hospital randomised controlled
trial [26], worked well on a practical level: packs were
available for all participating clinicians and recruited pa-
tients and the system for data collection was reliable
with all data collection forms being returned by post or
electronically. Most data were available through the
usual electronic patient record (ePCR) and so routine
use of an electronic ambulance patient record would be
an important requirement for participating sites in a de-
finitive trial.
Not all ECGs, however, were captured and overall a
post-VM ECG was missing or illegible in 7% of partici-
pants. This is an important consideration in determining
the primary outcome of a definitive trial. Cardioversion,
as determined by the treating clinician at the time, could
be used but confirmatory ECG evidence would be desir-
able. However, as shown by our independent ECG re-
views, these can still be potentially misleading due to
recurrence or spontaneous resolution of the arrhythmia.
Strict timing of the post-VM ECGs, e.g.1 min post-VM,
is unlikely to be practical in the pre-hospital setting.
Non-conveyance would be a reliable and easier out-
come to confirm but non-conveyance after cardioversion
remains relatively low and may not be universally advo-
cated among ambulance trusts.
Over a fifth of the participants had an ineligible
rhythm on retrospective expert review of their initial
ECG. The exclusion of non re-entrant type SVT such as
AF and other tachycardias that mimic SVT can be chal-
lenging even for experts. In a study conducted by emer-
gency physicians in hospital, 8% of recruited participants
were found to have an ineligible rhythm [6] and ECG in-
terpretation by paramedics in the pre-hospital environ-
ment is likely to be more challenging. This study was
pragmatic; a key inclusion criterion being detection of
an SVT that the treating clinician identified as eligible
for a valsalva manoeuvre. There is no evidence that vagal
manoeuvres are harmful if used in an attempt to treat
these excluded rhythms in the absence of contraindica-
tions. However, as it is unlikely to be successful, inclu-
sion of such ‘ineligible’ participants would need to be
taken into account to ensure adequate power to detect a
difference in cardioversion or conveyance rates.
Available feedback from both participants and clinicians
were broadly supportive of the trial design and a future
definitive trial. However, challenges for participants and
clinicians associated with delivering a randomised clinical
trial in this setting, such as the recruitment of sufficient
clinicians and patients are substantial and are very unlikely
to capture anywhere near the numbers of SVT patients
treated in routine practice. In addition, the limitations on
taking in trial information highlighted by the participant
feedback should further inform approaches to the consent
process in the design of a definitive trial.
A definitive trial would also need a health economic
analysis to take into account the cost of using a VAD, over
current cheap alternatives, and any subsequent emergency
care. This would add cost to such a trial and be challen-
ging to accommodate within a limited trial budget.
Careful consideration should therefore be made for
changes to the design of this study to mitigate against these
recruitment, consent and trial cost challenges. Methodolo-
gies such as a stepped-wedge design, allowing the recruit-
ment of participants during controlled changes to routine
care, might be one option to overcome such challenges.
Conclusions
We have completed a pre-hospital randomised con-
trolled feasibility trial of the use a VAD to treat SVT,
compared to standard care. This has shown recruiting
sufficient numbers of clinicians and participants to a de-
finitive trial of the same design would be challenging
and likely to require participation of several large ambu-
lance trusts. Although the treatment allocation and data
collection processes used in this feasibility study design
were efficient and could support a definitive trial, issues
associated with case identification, consent processes
and potential primary outcome selection remain a chal-
lenge. Design modification should be considered to help
overcome these challenges.
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